中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

139 records (took 0.091 seconds)

    Bicyclic derivatives as modulators of voltage gated ion channels
    93.
    发明专利
    Bicyclic derivatives as modulators of voltage gated ion channels 未知

    公开(公告)号：NZ567132A

    公开(公告)日：2011-12-22

    申请号：NZ56713206

    申请日：2006-09-08

    Applicant: VERTEX PHARMA

    Inventor： KAWATKAR AARTI ,  NEUBERT TIMOTHY ,  ZIMMERMANN NICOLE ,  MARTINBOROUGH ESTHER ,  TERMIN ANDREAS

    IPC: C07D417/12 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4709 ,  A61P25/00 ,  C07D277/52

    Abstract: Disclosed herein are sulphonamide derivatives of formula (I), wherein the substituents are as defined within the specification, processes for their preparation, pharmaceutical compositions comprising said compounds. Such compounds are useful for treating or lessening the severity of a disease, disorder, or condition selected from acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epileptic conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, stroke, bipolar disorders, or cancer pain.

    Quinazolines useful as modulators of voltage gated ion channels
    94.
    发明专利
    Quinazolines useful as modulators of voltage gated ion channels 未知

    公开(公告)号：NZ568393A

    公开(公告)日：2011-08-26

    申请号：NZ56839306

    申请日：2006-11-13

    Applicant: VERTEX PHARMA

    Inventor： WILSON DEAN ,  FANNING LEV T D ,  KRENITSKY PAUL ,  TERMIN ANDREAS ,  JOSHI PRAMOD ,  SHETH URVI

    IPC: C07D403/04 ,  A61K31/505 ,  A61P29/00

    Abstract: Disclosed are substituted quinazoline compound of formula (IA) or formula (IB), wherein the variables are as defined in the specification, which have the activity as inhibitors of voltage-gate sodium channels, and are suitable for use in the treatment of disease, condition, or disorder that is implicated in the activation or hyperactivity of voltage-gated sodium channels, wherein the disease, condition, or disorder is selected from acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, or cancer pain.

Patent Agency Ranking